Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion to Expand Rare Disease Portfolio with VYKAT XR
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion to Expand Rare Disease Portfolio with VYKAT XR
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $53 per share in cash, totaling $2.9 billion equity value, announced on April 6, 2026. 1 2 VYKAT XR (diazoxide choline) is the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, approved in March 2025, generating $190 million in 2025 revenue. 1 3 The deal expands Neurocrine's portfolio to three first-in-class medicines: INGREZZA, CRENESSITY, and VYKAT XR, strengthening its position in endocrinology and rare diseases. 1 The acquisition offers a 34-51% premium to Soleno's recent share prices and is expected to close within 90 days. 2 3 Analysts view the deal as strategically sound for Neurocrine but surprising for Soleno given VYKAT XR's growth potential. 3 Sources: 1. https://www.biospace.com/press-releases/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio 2. https://www.statnews.com/2026/04/06/neurocrine-biosciences-soleno-thera...
- Get link
- X
- Other Apps